Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 14/20 | 0.65 |
| ▸ | LPAR2 | Q9HBW0 | 8/20 | 0.65 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | CDC25A | P30304 | 1/20 | 0.43 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18272681 | 0.98 | LPAR3 (0.69) | LPAR3LPAR2LPAR1CYP3A4LPAR5 | |
| SCHEMBL27935494 | 0.98 | LPAR3 (0.69) | LPAR3LPAR2LPAR1CYP3A4LPAR5 | |
| SCHEMBL17626411 | 0.98 | LPAR3 (0.63) | LPAR3LPAR2LPAR1CYP3A4LPAR5 | |
| SCHEMBL17626568 | 0.98 | LPAR3 (0.63) | LPAR3LPAR2LPAR1CYP3A4LPAR5 | |
| SCHEMBL15281699 | 0.98 | LPAR3 (0.69) | LPAR3LPAR2LPAR1CYP3A4LPAR5 | |
| SCHEMBL18715371 | 0.98 | LPAR3 (0.69) | LPAR3LPAR2LPAR1CYP3A4LPAR5 | |
| SCHEMBL17626485 | 0.98 | LPAR3 (0.63) | LPAR3LPAR2LPAR1CYP3A4LPAR5 | |
| SCHEMBL2486762 | 0.93 | CYP3A4 (0.58) | LPAR3LPAR2LPAR1CYP3A4 | |
| SCHEMBL18686723 | 0.93 | LPAR3 (0.54) | LPAR3LPAR2LPAR1CYP3A4LPAR5 | |
| SCHEMBL17626420 | 0.91 | CYP3A4 (0.56) | LPAR3LPAR2LPAR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12100809-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-09-24 | — | — | US | disclosed |
| CN-112778511-B | Catalyst composition for polyester production process | 科莱恩塑料和涂料有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-20220149436-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-05-12 | — | — | US | disclosed |
| US-11283107-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-03-22 | — | — | US | disclosed |
| CN-113632282-A | Electrolyte for secondary battery and secondary battery | 株式会社村田制作所 | 2021-11-09 | — | — | CN | disclosed |
| EP-3621141-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2020-03-11 | — | — | EP | disclosed |
| US-20190229372-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2019-07-25 | — | — | US | disclosed |
| US-10333172-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2019-06-25 | — | — | US | disclosed |
| US-10290901-B2 | — | — | 2019-05-14 | — | — | US | disclosed |
| US-9608291-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2017-03-28 | — | — | US | disclosed |
| US-7749975-B2 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends | IDERA PHARMACEUTICALS, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20100166805-A1 | Modulation of immunostimulatory properties by small oligonucleotide-based compounds | IDERA PHARMACEUTICALS, INC. | 2010-07-01 | — | — | US | disclosed |
| US-7713535-B2 | Modulation of immunostimulatory properties by small oligonucleotide-based compounds | IDERA PHARMACEUTICALS, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20090325065-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2009-12-31 | — | — | US | disclosed |
| US-7632822-B2 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides | IDERA PHARMACEUTICALS, INC. (US) | 2009-12-15 | — | — | US | disclosed |
| US-7595305-B2 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides | IDERA PHARMACEUTICALS (US) | 2009-09-29 | — | — | US | disclosed |
| US-7517862-B2 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends | IDERA PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| EP-2012386-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | Mitsubishi Chemical Corporation (JP) | 2009-01-07 | — | — | EP | disclosed |
| US-7407944-B2 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends | IDERA PHARMACEUTICALS, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| US-20070173469-A1 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends | HYBRIDON, INC. | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100166805-A1 | Modulation of immunostimulatory properties by small oligonucleotide-based compounds | TLR3, ENTPD5, TLR5 | LPAR3 1251/4885LPAR2 1570/4885LPAR1 1973/4885 |
| US-20070173469-A1 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends | TLR5, TLR3, TLR9 | LPAR3 1179/4885LPAR2 1594/4885LPAR1 1788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.